Table 2 Characteristics of the IMRD patients with SARS-Cov-2 infection

Age, mean (SD)

50.1 (14.2)

47.0 (13.6)

51.2 (14.7)

<0.001

49.69 (14.28)

Male, n (%)

472 (18.6)

190 (18.2)

179 (15.4)

0.048

841 (17.7)

Use of glucocorticoids, n (%)

930 (36.7)

380 (36.4)

503 (43.1)

<0.001

1813 (38.2)

Use of rituximab, n (%)

63 (2.5)

37 (3.5)

64 (5.5)

<0.001

164 (3.5)

Diabetes, n (%)

167 (6.6)

127 (12.2)

154 (13.2)

<0.001

448 (9.4)

Chronic kidney disease, n (%)

49 (1.9)

61 (5.8)

39 (3.3)

<0.001

149 (3.1)

Rheumatic disease activity, n (%)

<0.001

 Remission

863 (36.0)

248 (33.1)

517 (48.6)

162 (3.8)

 Low

1022 (42.7)

235 (31.3)

317 (29.8)

1574 (37.4)

 Moderate

431 (18.0)

217 (28.9)

196 (18.4)

844 (20.1)

 High

79 (3.3)

50 (6.7)

33 (3.1)

1628 (38.7)

Immune-mediated inflammatory disease, n (%)

<0.001

 IJD

1405 (55.4)

509 (48.8)

708 (60.7)

2622 (55.3)

 CTD/Vasculitis

938 (37.0)

475 (45.5)

375 (32.2)

1788 (37.7)

 Other diseases

191 (7.5)

60 (5.7)

83 (7.1)

334 (7.0)

Number of comorbidities, n (%)

<0.001

 0

1617 (63.8)

410 (39.3)

645 (55.3)

2672 (56.3)

 1

492 (19.4)

367 (35.2)

345 (29.6)

1204 (25.4)

 2

282 (11.1)

202 (19.3)

131 (11.2)

615 (13.0)

 3

101 (4.0)

49 (4.7)

35 (3.0)

185 (3.9)

 ≥4

42 (1.7)

16 (1.5)

10 (0.9)

68 (1.4)

Physicians per 1000 habitants

 (1.06,8.8], n (%)

2172 (85.7)

1042 (100.0)

1166 (100.0)

<0.001

4380 (92.4)

 (8.85,16.6], n (%)

362 (14.3)

0 (  0.0)

0 (  0.0)

362 (7.6)

Average Income (USD per month)

 (169,437], n (%)

2164 (85.4)

606 (58.2)

343 (29.4)

<0.001

3113 (65.6)

 (438,707], n (%)

370 (14.6)

436 (41.8)

823 (70.6)

1629 (34.4)

Gini index

 (0.297,0.421], n (%)

950 (37.5)

26 (2.5)

160 (13.7)

<0.001

1136 (24.0)

 (0.422,0.548], n (%)

1584 (62.5)

1016 (97.5)

1006 (86.3)

3606 (76.0)

Unemployment rate (%)

 (1.56,10.1], n (%)

1673 (66.0)

118 (11.3)

1166 (100.0)

<0.001

2957 (62.4)

 (10.2,18.8], n (%)

861 (34.0)

924 (88.7)

0 (  0.0)

1785 (37.6)

MHDI

 (0.69,0.786], n (%)

0 (  0.0)

424 (40.7)

878 (75.3)

<0.001

1302 (27.5)

 (0.787,0.884], n (%)

2534 (100.0)

618 (59.3)

288 (24.7)

3440 (72.5)

Population density (hab/km²)

 (0.2, 3131.0], n (%)

2534 (100.0)

1042 (100.0)

713 (61.1)

<0.001

4289 (90.4)

 (3131.1–6262.8] n (%)

0 (  0.0)

0 (  0.0)

453 (38.9)

453 (9.6)

SARS-CoV-2 infection during vaccination period, n (%)

1419 (56.0)

62 (5.9)

328 (28.1)

<0.001

2935 (61.9)

Predominant SARS-CoV-2 viral variant, n (%)

<0.001

 Delta

47 (1.9)

6 (0.6)

127 (10.9)

180 (3.8)

 Gamma

582 (23.0)

34 (3.3)

10 (0.9)

626 (13.2)

 Omicron

246 (9.7)

1 (0.1)

62 (5.3)

3629 (76.5)

 Other variants

1659 (65.5)

1003 (96.1)

967 (82.9)

309 (6.5)

Stringency Index, mean (SD)

75.3 (17.7)

72.8 (10.8)

61.2 (21.3)

<0.001

71.28 (18.38)

Dead due to COVID-19, n (%)

101 (4.0)

44 (4.2)

110 (9.4)

<0.001

255 (5.4)